Artelo Biosciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Cover
- Cover
Financial Statements
Notes to Financial Statements
Accounting Policies
- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
Notes Tables
Notes Details

INTANGIBLE ASSET

INTANGIBLE ASSET	12 Months Ended
Dec. 31, 2023
INTANGIBLE ASSET
INTANGIBLE ASSET	NOTE 6– INTANGIBLE ASSET The Company has capitalized the costs associated with acquiring the exclusive worldwide license to develop and commercialize products comprising or containing the compound ART27.13 as an intangible asset at a value of $2,039 as of December 31, 2023, and December 31, 2022. The amount capitalized consisted of a $1,500 payment and the fair value of 4,087 shares of Common Stock of $539. During the year ended December 31, 2023, no additional costs met the criteria for capitalization as an intangible asset.

INTANGIBLE ASSET

12 Months Ended

Dec. 31, 2023

INTANGIBLE ASSET

INTANGIBLE ASSET

NOTE 6– INTANGIBLE ASSET

The Company has capitalized the costs associated with acquiring the exclusive worldwide license to develop and commercialize products comprising or containing the compound ART27.13 as an intangible asset at a value of $2,039 as of December 31, 2023, and December 31, 2022.

The amount capitalized consisted of a $1,500 payment and the fair value of 4,087 shares of Common Stock of $539. During the year ended December 31, 2023, no additional costs met the criteria for capitalization as an intangible asset.